Big Pharma set a new record for lobbying spending in 2025 — and 2026 is shaping up to be another year of big spending, as the industry seeks to influence U.S. healthcare policy.
The pharmaceutical and health industry combined spent $456.9 million on lobbying expenses in 2025, according to OpenSecrets, up 16.7% from 2024. According to The Boston Globe (citing STAT), it was the largest-ever single-year increase in lobbying spending.
This spending was part of what OpenSecrets called a “record” $868 million in lobbying outlays by the healthcare sector in 2025.
Big Pharma’s leading trade group — the Pharmaceutical Research and Manufacturers of America (PhRMA) — led the way, spending nearly $38 million on lobbying last year, a 22% increase from 2024, according to Politico. PhRMA was joined by “nine of the 13 U.S. drugmakers on the Fortune 500,” who reported “their highest spending in at least a decade” on lobbying.
There are no signs of a slowdown. OpenSecrets data show the pharmaceutical industry has reported $245.7 million in lobbying expenses so far this year, part of the $459.3 million the health sector overall has spent in 2026.
PhRMA spent a reported $19.8 million in lobbying expenses in 2026, ranking third among business and trade organizations this year — a position it also held in 2025, when it spent $38.19 million.
Among drugmakers, Eli Lilly has spent over $7 million on lobbying this year. Pfizer has spent $6.62 million, and Merck has spent $6.58 million.
According to OpenSecrets, PhRMA’s record spending bucked the overall trend, in which “some of Washington’s biggest spenders, such as the U.S. Chamber of Commerce and the National Association of Realtors, cut back from their 2024 lobbying expenditures.”
